

About SK life science

SK Life Science, Inc. is part of something bigger. Established in 2002 and located in Paramus, NJ, SK life science is committed to accelerating the development of next-generation treatments for disorders of the central nervous system (CNS). It is a U.S. subsidiary of SK Biopharmaceuticals, Co., Ltd., a company focused on discovery, development and commercialization of innovative medicines. Both companies are a part of SK Group, one of the largest conglomerates in Korea and a global leader in the energy, chemical, semiconductor and telecommunications industries.¹




Our Vision

By taking on the mysteries of the brain, **we strive to make life better.**

Our pipeline sets the stage for success in CNS

SK Biopharmaceuticals and SK life science have discovered and developed two compounds which ultimately received U.S. FDA approval: a treatment for sleep disorder which was out-licensed to Jazz Pharmaceuticals, and a treatment for partial-onset seizures, which is being commercialized independently by SK life science in the U.S. With this strong track record of research and discovery in CNS, the companies are continuing to explore new compounds that can address unmet patient needs. The companies have eight compounds in development for the treatment of CNS disorders including epilepsy, Lennox-Gastaut syndrome and attention-deficit/hyperactivity disorder, among others.



Making a difference in epilepsy

Epilepsy is a condition of the brain characterized by seizures. Nearly 65 million people suffer from epilepsy worldwide, including 3.4 million people in the U.S.² The vast majority of people with epilepsy (60%) have partial onset-seizures, which begin in just one part of the brain.³

Having seizures is associated with debilitating and life-altering complications. Despite the availability of many anti-epileptic drugs, nearly 60% of patients with epilepsy continue to have seizures, many with more than three seizures per year, according to the Centers for Disease Control and Prevention.⁴

Epilepsy is associated with numerous complications, including:^{5,6,7}

- Risk of injury
- Cognitive impairment
- Unemployment & underemployment
- Poor quality of life
- Dependency
- Sudden unexpected death in epilepsy (SUDEP)
- Depression & anxiety


Our values define us

SK life science is defined by our values and driven by the unmet needs of patients, HCPs, caregivers, and the CNS community. Our values are more than words on a page – they are what you can expect from us:

- Empower excellence
- Embody a pioneering spirit
- Be fully engaged
- Always do the right thing
- Appreciate & recognize people
- Inspire happiness!

Leadership

With deep experience in drug development and commercialization in the U.S. and Korea, our leadership team is ready, willing and able to break conventions to address the unmet needs in CNS.



Follow Us



Contact Us

General business
Info@sklsi.com

Strategic alliance & partnership opportunities
Partnerships@sklsi.com

Media inquiries & PR
Media@sklsi.com

¹ Cho Chung-un, SK likely to overtake Hyundai as Korea's 2nd-largest conglomerate. The Korea Herald, February 20, 2019. http://knews.kherald.com/view.php?id=2019022000639&md=20190223003215_BL, Accessed October 2, 2019.
² CURE. What is epilepsy? <https://www.cureepilepsy.org/about-epilepsy/what-is-epilepsy>, Accessed October 2, 2019.
³ National Institute of Neurological Disorders and Stroke. The Epilepsies and Seizures: Hope through Research.
⁴ Tian N, Boring M, Kobau R, Zack MM, Croft JB. Active Epilepsy and Seizure Control in Adults - United States, 2013 and 2015. *MMWR Morb Mortal Wkly Rep.* 2018;67(15):437-442.
⁵ Epilepsy Foundation. Staying Safe. <https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe>, Accessed October 2, 2019.
⁶ Epilepsy Foundation. Challenges with Epilepsy. <https://www.epilepsy.com/learn/challenges-epilepsy>, Accessed October 2, 2019.
⁷ Epilepsy Foundation. Social Concerns. <https://www.epilepsy.com/learn/challenges-epilepsy/social-concerns>, Accessed October 2, 2019.